Cargando…
Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival
Receptor tyrosine kinase AXL (RTK-AXL) is regarded as a suitable target in glioblastoma (GBM) therapy. Since AXL kinase inhibitors are about to get approval for clinical use, patients with a potential benefit from therapy targeting AXL need to be identified. We therefore assessed the expression patt...
Autores principales: | Onken, Julia, Vajkoczy, Peter, Torka, Robert, Hempt, Claudia, Patsouris, Victor, Heppner, Frank L., Radke, Josefine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584143/ https://www.ncbi.nlm.nih.gov/pubmed/28881571 http://dx.doi.org/10.18632/oncotarget.18468 |
Ejemplares similares
-
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016) -
Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019) -
Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
por: Scherschinski, Lea, et al.
Publicado: (2022) -
AXL is an oncotarget in human colorectal cancer
por: Martinelli, Erika, et al.
Publicado: (2015) -
Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation
por: Lauter, Markus, et al.
Publicado: (2019)